Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

A pill vs. a shot: which eases Kidney-Related anemia better?

NCT ID NCT07755683

Disease control Sponsor: Services Hospital, Lahore Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 10, 2026 · Last updated Aug 11, 2026 · Updated 1 time

Summary

This trial asks whether an oral medication called daprodustat can match the effectiveness of the injectable drug epoetin alpha in treating anemia linked to chronic kidney disease. Adults with stage 3-5 kidney disease who are not on dialysis and have low hemoglobin levels will receive either daprodustat pills or epoetin alpha injections for one month. Researchers will compare changes in hemoglobin and ferritin levels to see if the pill offers a viable, more convenient alternative to injections.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
daprodustat (an oral medication) and epoetin alpha (an injectable medication)
What this could lead to
If daprodustat works as well as epoetin alpha, it could offer a convenient pill alternative to injections for managing anemia in chronic kidney disease.
What could go wrong
This is a small, short-term study (60 people, one month) that only measures blood markers, not long-term outcomes. Results may not apply to everyone, and daprodustat may have side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 60 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Feb 2027

An estimate. End dates often move.

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age 18-65 years, either gender. 2. Confirmed CKD stage 3, 4, or 5. 3. Not currently receiving dialysis at time of screening. 4. Hemoglobin at presentation: 8.0-10 g/dL, serum ferritin \> 100 ng/mL at screening and transferrin saturation (TSAT) \> 20% at screening. Exclusion Criteria: 1. Clinically significant gastrointestinal bleeding, major surgery or RBCs transfusion in last 4 weeks 2. Pregnant, breast-feeding, not agreed to use contraception 3. Uncontrolled hypertension (\>180/100 mmHg). 4. Recent major cardiovascular event including acute coronary syndrome or stroke, or in the past 3 months, chronic liver disease (ALT OR AST \> 40 IU, hepatitis B or C) 5. Use of any experimental/investigational drug within 30 days of screening or know hypersensitivity against trial drugs 6. Active or high risk malignancy or treatment for malignancy with in the past 2 years. 7. Uncorrected iron deficiency despite iron supplementations. 8. Acute sepsis as evident by increase C-reactive protein (CRP), Total leukocyte count (TLC).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Anemia associated with chronic kidney disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

anemia anemia due to chronic disorder chronic kidney disease chronic renal failure syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Anemia associated with chronic kidney disease Chronic kidney disease (stages 3B-5)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Services Hospital Lahore Pakistan

    Lahore, Punjab Province, 54000, Pakistan

More trials for these conditions

Other studies related to the condition(s) this trial covers.